"instanceType","rationale","versionIdentifier","id","uuid:ID"
"StudyVersion","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","StudyVersion_1","5236be72-ab28-41ce-82a1-c397b5f4abe4"
